Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
L Yang, Z Wang - European Journal of Medicinal Chemistry, 2023 - Elsevier
The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: a rapid review and meta‐analysis
This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …
[HTML][HTML] Real-world COVID-19 vaccine effectiveness against the Omicron BA. 2 variant in a SARS-CoV-2 infection-naive population
Abstract The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and
escape of vaccine-derived immunity. Although first-generation vaccines remain effective …
escape of vaccine-derived immunity. Although first-generation vaccines remain effective …
Nirmatrelvir for vaccinated or unvaccinated adult outpatients with Covid-19
J Hammond, RJ Fountaine, C Yunis… - … England Journal of …, 2024 - Mass Medical Soc
Background Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients …
[HTML][HTML] Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
B Cao, Y Wang, H Lu, C Huang, Y Yang… - … England Journal of …, 2024 - Mass Medical Soc
Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …
[HTML][HTML] Vaccines and therapeutics for immunocompromised patients with COVID-19
The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …
This diverse group is at increased risk for impaired vaccine responses, progression to …
[HTML][HTML] Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK
Background Evidence on post-acute sequelae of SARS-CoV-2 (PASC) has shown
inconsistent findings. This study aimed to generate coherent evidence on the post-acute …
inconsistent findings. This study aimed to generate coherent evidence on the post-acute …
[HTML][HTML] Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Effectiveness of COVID-19 treatment with nirmatrelvir–ritonavir or molnupiravir among US veterans: target trial emulation studies with one-month and six-month …
KL Bajema, K Berry, E Streja, N Rajeevan… - Annals of internal …, 2023 - acpjournals.org
Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in hospitalized patients with COVID-19: a target trial emulation study
Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …